

Children’s Oncology Group’s 2023 Blueprint for Research: Rare Tumors

Kris Ann Schultz¹, Murali Chintagumpala², Jin Piao³, Kenneth Chen⁴, Robyn Gartrell⁵, Emily Christison-Lagay⁶, Jesse Berry⁷, Rachana Shah³, and Theodore Laetsch⁸

¹Children’s Minnesota Minneapolis Specialty Center

²Baylor College of Medicine Department of Pediatrics

³University of Southern California Keck School of Medicine

⁴The University of Texas Southwestern Medical Center

⁵Columbia University

⁶Yale School of Medicine

⁷Children’s Hospital Los Angeles

⁸University of Pennsylvania

July 5, 2023

Abstract

The Children’s Oncology Group (COG) Rare Tumor committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that don’t fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.

Hosted file

RAR Blueprint 2023 FINAL 6.20.23.doc available at <https://authorea.com/users/323788/articles/653003-children-s-oncology-group-s-2023-blueprint-for-research-rare-tumors>